EUCTR2017-003228-54-ES进行中（未招募）1 期
A Phase IIa (proof of concept), randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to moderate ulcerative colitis.
PaloBiofarma S.L.0 个研究点目标入组 30 人开始时间: 2018年4月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria for study entry:
- •-Able and willing to provide written informed consent
- •-Male or Female, 18 to 75 years of age, inclusive
- •-Patient with previous diagnosis of ulcerative colitis (extensive or pancolitis, E3 of Montreal Classification) established at least 3 months prior to screening and determined by ordinary clinical, endoscopic, and histological procedures.
- •-Patient who has stable oral 5-ASA dose = 3 gr/day treatment, within 1 month prior to screening.
- •-Mild-to-moderate activity of the disease determined clinically during the screening period by Partial Mayo Clinical Score of = 6, with rectal bleeding score = 2 and/or a bowel frequency score = 2.
- •-Patient in flare of the disease.
- •-Patient with faecal calprotectin levels > 50 mg/Kg
- •-Availability for the entire study period, absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; willingness to adhere to the protocol requirements, ability to cooperate adequately, to understand and follow the instructions of the physician or designee.
- •-Women who are not postmenopausal (at least 12 months) or surgically sterile must have a negative pregnancy test at screening and at the end of study and either abstain from sexual intercourse or use a highly effective method of birth control for the duration of the study and after 12 weeks after the last dose of study drug.
- •-For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm for the duration of the study and after 12 weeks from the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Patients must not meet any of the following criteria for study entry:
- •-Patient who has treatment, within 3 months prior to screening, with immunomodulators including corticosteroids, azatioprine, mercaptopurine, biologics, tacrolimus, cyclosporine, for disease control.
- •-Patient who has stable oral 5-ASA dose > 3 gr/day treatment, within 1 month prior to screening.
- •-Patient with C-reactive Protein levels (CRP) = 10 mg/L
- •-Patient who has topic 5-ASA treatment, within 1 month prior to screening.
- •-Patient who has anti-diarrheal treatment, within 3 months prior to screening.
- •-Use of prescription medications started or with a dose adjustment within 4 weeks prior to study enrolment, or OTC medications or supplements started or with a dose adjustment within 2 weeks prior study enrolment.
- •-Use of products, food supplements or medical devices, whose composition includes probiotics in the 3 months prior to the selection.
- •-Patient who has fulminant or severe colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of colitis associated colonic dysplasia or active peptic ulcer disease.
- •-Patient who has prior extensive colonic resection, subtotal or total colectomy or planned surgery for UC
- •-Patient who has past or present fistula or abdominal abscess
- •-Patient who has clinically significant diseases and/or infections captured in the medical history or evidence of clinically significant findings on physical examination and/or clinically significant ordinary laboratory evaluations (haematology, biochemistry, and urinalysis) or ECG.
- •-Patient who has evidence of significant liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- •-Patient who is currently participating in another clinical trial of an investigational drug or medical device within 90 days prior to screening.
- •-Patient who is pregnant or lactating
- •-Inability to comply with study protocol, in opinion of the investigator
- •-History of alcohol, drug or chemical abuse within 6 months prior to screening
- •-History of cancer except local basal or squamous cell carcinoma of the skin that has been excised and is considered cured.
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Test the Efficacy, Safety and Tolerability of Two Dosing Regimens of Cholestyramine Coated Capsules in Adults with Short Bowel SyndromeBile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS)MedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10080049Term: Bile acid diarrheaSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-004419-32-PLPharmascience Inc.18
进行中（未招募）
1 期
MK-7264 Phase 2a in Women with Endometriosis-related PaiModerate to severe Endometriosis-related pain (ERP)MedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2018-001098-26-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.187
进行中（未招募）
1 期
MK-7264 Phase 2a in Women with Endometriosis-related PaiModerate to severe Endometriosis-related pain (ERP)MedDRA version: 21.1Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2018-001098-26-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.166
进行中（未招募）
1 期
A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial spondyloarthritis including those previously exposed to anti-TNF therapy (NAMASTE study)moderate-to-severe axial spondyloarthritisMedDRA version: 20.0Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-000176-15-GBIzana Bioscience Limited42
招募中
1 期
Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy in adult patients with Acute Respiratory Distress SyndromeMedDRA version: 21.1Level: PTClassification code: 10001052Term: Acute respiratory distress syndrome Class: 100000004855Acute Respiratory Distress SyndromeCTIS2024-512621-88-00Dompe' Farmaceutici S.p.A.66